Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 2;29(158):200289.
doi: 10.1183/16000617.0289-2020. Print 2020 Dec 31.

Current developments and future directions in COPD

Alexander G Mathioudakis  1   2 , Lowie E G W Vanfleteren  3 , Lies Lahousse  4 , Andrew Higham  5   2 , James P Allinson  6 , Carolina Gotera  7 , Dina Visca  8   9 , Dave Singh  5   2   10 , Antonio Spanevello  8   9
Affiliations

Current developments and future directions in COPD

Alexander G Mathioudakis et al. Eur Respir Rev. .

Abstract

The European Respiratory Society journals publish respiratory research and policy documents of the highest quality, offering a platform for the exchange and promotion of scientific knowledge. In this article, focusing on COPD, the third leading cause of death globally, we summarise novel research highlights focusing on the disease's underlying mechanisms, epidemiology and management, with the aim to inform and inspire respiratory clinicians and researchers.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.G. Mathioudakis has nothing to disclose. Conflict of interest: L.E.G.W. Vanfleteren reports grants and personal fees from AstraZeneca, and personal fees from Novartis, GSK, Chiesi, Menarini, Pulmonx, Resmed, Boehringer, Verona Pharma and AGA Linde outside the submitted work. Conflict of interest: L. Lahousse reports Society awards sponsored by AstraZeneca and Chiesi; and has provided expert consultation for Boehringer Ingelheim GmbH and Novartis, outside the submitted work. Conflict of interest: A. Higham reports personal fees from Chiesi Pharmaceuticals, outside the submitted work. Conflict of interest: J.P. Allinson reports personal fees from Pulmonx, and non-financial support from GSK and Boehringer Ingelheim, outside the submitted work. Conflict of interest: C. Gotera has nothing to disclose. Conflict of interest: D. Visca has nothing to disclose. Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work. Conflict of interest: A. Spanevello has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Basic mechanisms. Schematic diagram illustrating some of the studies published in European Respiratory Society journals which provide important insights into the basic mechanisms of COPD pathophysiology. ACE2: angiotensin converting enzyme 2; BMI: body mass index; BMP4: bone morphogenetic protein 4; IL-13: interleukin-13; ILC2: type 2 innate lymphoid cell; MMP-12: matrix metalloproteinase-12; T2: type 2; Th2: T-helper 2 lymphocytes.
FIGURE 2
FIGURE 2
Barriers and enablers to pulmonary rehabilitation referral and uptake. PR: pulmonary rehabilitation; GP: general practitioner. Reproduced from [79] with permission.
See this image and copyright information in PMC

References

    1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1151–1210. doi:10.1016/S0140-6736(17)32152-9 - DOI - PMC - PubMed
    1. Singh D, Agusti A, Anzueto A, et al. . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019; 53: 1900164. doi:10.1183/13993003.00164-2019 - DOI - PubMed
    1. Agusti A, Bel E, Thomas M, et al. . Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410–419. doi:10.1183/13993003.01359-2015 - DOI - PubMed
    1. Mathioudakis AG, Janssens W, Sivapalan P, et al. . Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax 2020; 75: 520–527. doi:10.1136/thoraxjnl-2019-214484 - DOI - PMC - PubMed
    1. Schleich F, Bikov A, Mathioudakis AG, et al. . Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Res 2019; 5: 00225-2018. doi:10.1183/23120541.00225-2018 - DOI - PMC - PubMed

MeSH terms